Hologic Receives FDA Clearance for SecurViewDX™ Breast Imaging Workstation

BEDFORD, Mass., Aug. 12, 2004 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of women's diagnostic imaging systems and state-of- the-art digital imaging systems, today announced receipt of marketing clearance from the Food and Drug Administration (FDA) for its SecurViewDX breast imaging workstation. The SecurViewDX is a dedicated, multi-modality workstation for display and interpretation of any screening or diagnostic digital mammogram, as well as other images, such as MRI, CT, PET and ultrasound. The workstation will also support digital computer aided detection (CAD) programs.

"This is an important milestone in Hologic's breast imaging development program," said Jack W. Cumming, Hologic's Chairman and CEO. "The ability to use our dedicated workstation to view digital mammograms from any vendor, as well as images from other modalities, should have a significant impact on improved workflow in breast imaging suites. In addition, physicians will now be able to use our package of highly specialized image manipulation tools on virtually any digital mammogram. These tools have been developed in close cooperation with clinical end-users to support high quality, high volume diagnostic case review. We believe the SecurViewDX will play an important role in helping breast imaging practices achieve increased efficiencies and better diagnostic outcomes."

The SecurViewDX joins Hologic's portfolio of imaging products focused on the early detection of breast cancer and osteoporosis, including the Lorad Selenia™ full field digital mammography (FFDM) system, incorporating the Company's proprietary amorphous selenium direct conversion technology. Hologic's product lines include state-of-the-art screen-film mammography systems, stereotactic breast biopsy equipment, and an array of bone densitometry products.

Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information visit

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated performance and benefits of the SecurView. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for digital X-ray products; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; risks relating to Hologic's reliance on a single source of supply for some key components of its products; the need to comply with especially high standards in the manufacture of digital X-ray products; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.

   Glenn P. Muir                      Frances Crecco
   Executive Vice President & CFO     Director, Investor Relations
   Hologic, Inc.                      Hologic, Inc.
   (781) 999-7300                     (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300,
or Frances Crecco, Director, Investor Relations, +1-781-999-7377 both of
Hologic, Inc.

Web site: